A synthetic strategy to access a novel family of nucleoside analogues bearing a C3'-nitrile substituted all-carbon quaternary center is presented herein. These purine bearing scaffolds were tested in two pancreatic cancer cell lines harboring either wild-type (BxPC3) or G12V KRAS (Capan2) mutations. A promising compound was shown to have significantly greater efficacy in the Capan2 cell line as compared to Gemcitabine, the clinical gold standard used to treat pancreatic cancer.

中文翻译：

---

鉴定胰腺癌细胞系生长的C3'-腈核苷类似物抑制剂。

本文提出了一种合成策略，该策略可访问带有C3'-腈取代的全碳四元中心的核苷类似物新家族。这些带有嘌呤的支架在两个具有野生型（BxPC3）或G12V KRAS（Capan2）突变的胰腺癌细胞系中进行了测试。与吉西他滨（一种用于治疗胰腺癌的临床金标准）相比，一种有希望的化合物在Capan2细胞系中具有显着更高的疗效。